ExeVir wins backing to develop llama-derived antibodies for COVID-19

By The Science Advisory Board staff writers

July 28, 2020 -- Belgian firm ExeVir Bio has closed on a 23 million euro ($26.9 million U.S.) series A financing round to support the development of its llama-derived antibody (VHH) technology in treating COVID-19.

The financing was led by Fund+, with the participation of Belgian life science research institute Vlaams Instituut voor Biotechnologie (VIB), UCB Ventures, the Belgian Federal Government via Société Fédérale de Participations et d'Investissement-Société Fédérale de Participations (SFPI-FPIM), V-Bio Ventures, and several Belgian family offices, according to ExeVir Bio. The company will use the funds to advance the antibody into clinical trials.

A spinoff of VIB, ExeVir Bio is utilizing its VHH technology to develop treatments for viral infections. Its lead asset, VHH782-Fc, binds to a unique epitope that is conserved in both SARS-CoV and SARS-CoV-2, preventing these viruses from entering the cell, according to the firm. As a result, it could be used as a therapeutic and a prophylactic.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here